Bayer Schering Pharma extends research in cancer-related targets
Bayer Schering Pharma of Germany has signed an exclusive licence agreement with California-based Celera that will give the company access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.
Bayer Schering Pharma of Germany has signed an exclusive licence agreement with California-based Celera that will give the company access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.
Bayer Schering Pharma will pay Celera a one-off fee for exclusive access to the five targets. Additional payments are due on achieving development and commercial milestones. Celera is entitled to royalties based on net sales of any commercialised product.
"This agreement allows us to expand our existing research portfolio in the area of cancer-related targets," said Professor Khusru Asadullah, head of target discovery at Bayer Schering Pharma. "We look forward to exploring the full potential of these promising target candidates with regard to therapeutic interference for anti-tumor therapy as well as in in-vivo diagnostic imaging."
